Biotech firm Candel Therapeutics announces a dual $200 million financing strategy, combining a royalty deal with RTW Investments and a public stock offering, to fund the potential U.S. commercialization of its lead prostate cancer immunotherapy, CAN-2409.
Piper Sandler and Barclays have raised price targets for CytomX Therapeutics (CTMX), citing promising early-phase data for its experimental colorectal cancer therapy. Updated results from a larger patient cohort are expected this quarter.
Candel Therapeutics outlines aggressive late-stage clinical and regulatory timelines for its lead candidate, aglatimagene besadenovec, in prostate cancer and NSCLC, backed by a strengthened balance sheet from recent strategic financings exceeding $300 million.
At the TD Cowen Healthcare Conference, Context Therapeutics CEO Martin Lehr detailed the biotech's strategy, highlighting imminent Phase 1 data for its Claudin 6-targeting therapy and the planned clinic entry for its Nectin-4 program in the second quarter.
Kairos Pharma strikes a deal with Celyn Therapeutics to secure worldwide rights to CL-273, a novel AI-designed inhibitor aimed at overcoming treatment resistance in EGFR-mutant non-small cell lung cancer, accelerating development in a multi-billion dollar market.
Reed Jobs, son of the late Apple co-founder Steve Jobs, has secured over $200 million for Yosemite, a venture fund dedicated to pioneering cancer treatments. Backed by major institutions, the fund seeks to transform cancer from a fatal diagnosis to a chronic, manageable disease within a generation.
The FDA has approved Merck's KEYTRUDA, including a new subcutaneous formulation, for use in platinum-resistant ovarian cancer, marking a significant expansion for the blockbuster drug. The move is paired with a new diagnostic and a collaboration on a women's health drug delivery platform, as Merck seeks to strengthen its market position amid a persistent valuation gap.
CytomX Therapeutics reports updated Phase 1 data for its masked antibody-drug conjugate Varseta-M, showing encouraging response rates and manageable safety in heavily pre-treated metastatic colorectal cancer patients, paving the way for registrational studies.
Kairos Pharma has secured exclusive worldwide rights to Celyn Therapeutics' CL-273, a next-generation EGFR inhibitor designed to overcome treatment resistance in non-small cell lung cancer, accelerating its path to a $16.2 billion market.
Allogene Therapeutics is set to release pivotal early data in April from its ALPHA3 trial, testing whether its 'off-the-shelf' CAR T therapy, cema-cel, can eliminate minimal residual disease in large B-cell lymphoma patients who have achieved remission—a strategy that could redefine frontline treatment.
In his first major remarks as CEO, Malte Peters outlined Tango Therapeutics' strategy to advance its lead drug vopimetostat into pivotal trials for pancreatic cancer, while revealing promising early enrollment for its RAS inhibitor combination studies.
The era of chemotherapy as the undisputed cornerstone of cancer treatment is evolving. While it remains a crucial tool, a new wave of targeted drugs and combination strategies is redefining patient care, offering hope for better outcomes and quality of life.
At a major industry conference, Bicara Therapeutics detailed encouraging clinical results for its lead bifunctional antibody, ficerasfusp alfa, in head and neck cancer. The company outlined its path to a potential 2027 regulatory filing and announced a substantial financing round to build commercial capabilities.
Shares of Tango Therapeutics (NASDAQ: TNGX) rallied more than 52% this week, fueled by a reaffirmed 'buy' rating and the initiation of key clinical trials for its lead pancreatic cancer drug candidate.
At the TD Cowen Healthcare Conference, Bicara Therapeutics detailed promising clinical data for its lead bifunctional antibody, FICERA, and outlined the pivotal path for its FORTIFY study in a hard-to-treat form of head and neck cancer, with potential regulatory filings on the horizon.
Clinical-stage biopharma Candel Therapeutics has priced a public offering of 18.3 million shares at $5.45 each, aiming to raise approximately $100 million. The funds are earmarked to advance the launch readiness of its lead prostate cancer candidate, CAN-2409, and support a pivotal Phase 3 trial in lung cancer.
Shares of CytomX Therapeutics surged more than 60% after its novel 'masked' antibody-drug conjugate demonstrated encouraging efficacy and a manageable safety profile in a Phase 1 trial for advanced colorectal cancer, a disease with limited late-line options.
Wedbush Securities has reaffirmed its bullish stance on Tango Therapeutics (TNGX), raising its price target to $19 following strong quarterly updates. The move underscores growing analyst confidence in the biotech firm's lead oncology candidate, vopimetostat.
Buoyed by a robust 2025 performance, Genmab executives project a pivotal 2026 filled with critical clinical readouts, setting the stage for multiple potential drug launches in 2027 that could solidify its standing as a leading independent oncology company.
Abbott's landmark acquisition of Exact Sciences underscores a strategic shift, as advanced genetic testing moves from guiding treatment to fundamentally accelerating drug discovery and development in the precision oncology era.
